TransCelerate BioPharma Awards Accenture New Clinical Data Sharing Services Contract
October 01 2015 - 8:33AM
Business Wire
Extends ongoing work focused on advancing
R&D innovation and improving clinical trials
Accenture (NYSE:ACN) has been selected by TransCelerate
BioPharma Inc., a non-profit organization focused on advancing
innovation in R&D for the biopharmaceutical industry, to
support its Placebo and Standard of Care initiative (PSoC). The
PSoC initiative has been established to maximize the value of
historic clinical data collected during clinical trials, and is the
first cross-therapeutic, multi-sponsor clinical data sharing
initiative of its kind in life sciences designed to improve trial
design and safety surveillance.
Accenture will help TransCelerate member companies better
aggregate, share, and use clinical data collected in the placebo
and standard-of-care arms of clinical trials. This agreement aims
to optimize the use and sharing of clinical data by ensuring it is
compliant with the standards set by the Clinical Data Interchange
Standards Consortium. Insights gained from the combined data have
the potential to reduce both the time spent on, and number of
patients involved in clinical trials; improve the patient
experience; and enable a better understanding of diseases.
Ed Bowen, Senior Director, Translational and Bioinformatics at
Pfizer and the lead for this initiative, said: “Having access to
this data among TransCelerate member companies has the potential to
be a powerful tool for clinical research. This initiative is
representative of TransCelerate's overall mission: to collaborate
across the global R&D community to identify, prioritize, design
and facilitate implementation of solutions designed to drive the
efficient, effective and high quality delivery of medicines.”
“Today the industry struggles to maximize the use of
historically collected clinical data to enhance prospective study
design, interpret safety signals and inform patient recruitment
strategies,” said Kevin Julian, managing director, Accenture
Accelerated R&D Services, Life Sciences. “Working with
TransCelerate we aim to provide a solution that helps strengthen
these capabilities quickly and efficiently for the industry.”
Accenture was chosen by TransCelerate in 2012 to provide program
management and change management services for the development and
adoption of the TransCelerate portfolio of initiatives. In
March 2015 Accenture also delivered a project to achieve an
automated solution that simplifies the process of sourcing
comparator drugs for TransCelerate’s Comparator Network
initiative.
“Accenture is an important collaborator with TransCelerate,”
said Dalvir Gill, CEO of TransCelerate BioPharma Inc. “Accenture’s
deep expertise in life sciences, technology, and clinical
data-related services will be instrumental in delivering a data
sharing solution. This new project builds on the multi-year
relationship between Accenture and TransCelerate.”
About TransCelerate BioPharma Inc.
TransCelerate BioPharma Inc. is a non-profit organization
dedicated to improving the health of people around the world by
accelerating and simplifying the research and development (R&D)
of innovative new therapies. The organization's mission is to
collaborate across the global R&D community to identify,
prioritize, design and facilitate implementation of solutions
designed to drive the efficient, effective and high quality
delivery of medicines. TransCelerate evolved from discussions at
various forums for executive R&D leadership to debate current
issues facing the industry and examine solutions for addressing
agreed-upon common challenges. The founding member companies are
AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb,
Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson,
Pfizer, the Roche Group, and Sanofi. Additional members that have
joined since the inception of TransCelerate include Allergan, Inc.,
Amgen, Astellas Pharma Inc., Biogen, EMD Serono, Inc. (a subsidiary
of Merck KGaA, Darmstadt, Germany), Medgenics, Inc., Merck &
Co., Inc., Novo Nordisk, Shionogi & Co., Ltd. and UCB.
Membership in TransCelerate is open to pharmaceutical and
biotechnology companies with Research and Development operations.
Executive offices are located in Philadelphia, PA. For more
information, please visit
http://www.transceleratebiopharmainc.com/.
About Accenture
Accenture is a global management consulting, technology services
and outsourcing company, with more than 358,000 people serving
clients in more than 120 countries. Combining unparalleled
experience, comprehensive capabilities across all industries and
business functions, and extensive research on the world’s most
successful companies, Accenture collaborates with clients to help
them become high-performance businesses and governments. The
company generated net revenues of US$31.0 billion for the fiscal
year ended Aug. 31, 2015. Its home page is www.accenture.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151001005030/en/
AccentureCam Granstra, +
1-312-693-5992cameria.l.granstra@accenture.comorTransCelerateVictoria
Aguiar, + 1-212-584-5470vicky@blissintegrated.com
Accenture (NYSE:ACN)
Historical Stock Chart
From Apr 2024 to May 2024
Accenture (NYSE:ACN)
Historical Stock Chart
From May 2023 to May 2024